Cargando…
Advances in Lung Cancer Treatment Using Nanomedicines
[Image: see text] Carcinoma of the lungs is among the most menacing forms of malignancy and has a poor prognosis, with a low overall survival rate due to delayed detection and ineffectiveness of conventional therapy. Therefore, drug delivery strategies that may overcome undesired damage to healthy c...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835549/ https://www.ncbi.nlm.nih.gov/pubmed/36643475 http://dx.doi.org/10.1021/acsomega.2c04078 |
_version_ | 1784868690780487680 |
---|---|
author | Sharma, Akshansh Shambhwani, Devanshi Pandey, Sadanand Singh, Jay Lalhlenmawia, Hauzel Kumarasamy, Murali Singh, Sachin Kumar Chellappan, Dinesh Kumar Gupta, Gaurav Prasher, Parteek Dua, Kamal Kumar, Deepak |
author_facet | Sharma, Akshansh Shambhwani, Devanshi Pandey, Sadanand Singh, Jay Lalhlenmawia, Hauzel Kumarasamy, Murali Singh, Sachin Kumar Chellappan, Dinesh Kumar Gupta, Gaurav Prasher, Parteek Dua, Kamal Kumar, Deepak |
author_sort | Sharma, Akshansh |
collection | PubMed |
description | [Image: see text] Carcinoma of the lungs is among the most menacing forms of malignancy and has a poor prognosis, with a low overall survival rate due to delayed detection and ineffectiveness of conventional therapy. Therefore, drug delivery strategies that may overcome undesired damage to healthy cells, boost therapeutic efficacy, and act as imaging tools are currently gaining much attention. Advances in material science have resulted in unique nanoscale-based theranostic agents, which provide renewed hope for patients suffering from lung cancer. Nanotechnology has vastly modified and upgraded the existing techniques, focusing primarily on increasing bioavailability and stability of anti-cancer drugs. Nanocarrier-based imaging systems as theranostic tools in the treatment of lung carcinoma have proven to possess considerable benefits, such as early detection and targeted therapeutic delivery for effectively treating lung cancer. Several variants of nano-drug delivery agents have been successfully studied for therapeutic applications, such as liposomes, dendrimers, polymeric nanoparticles, nanoemulsions, carbon nanotubes, gold nanoparticles, magnetic nanoparticles, solid lipid nanoparticles, hydrogels, and micelles. In this Review, we present a comprehensive outline on the various types of overexpressed receptors in lung cancer, as well as the various targeting approaches of nanoparticles. |
format | Online Article Text |
id | pubmed-9835549 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-98355492023-01-13 Advances in Lung Cancer Treatment Using Nanomedicines Sharma, Akshansh Shambhwani, Devanshi Pandey, Sadanand Singh, Jay Lalhlenmawia, Hauzel Kumarasamy, Murali Singh, Sachin Kumar Chellappan, Dinesh Kumar Gupta, Gaurav Prasher, Parteek Dua, Kamal Kumar, Deepak ACS Omega [Image: see text] Carcinoma of the lungs is among the most menacing forms of malignancy and has a poor prognosis, with a low overall survival rate due to delayed detection and ineffectiveness of conventional therapy. Therefore, drug delivery strategies that may overcome undesired damage to healthy cells, boost therapeutic efficacy, and act as imaging tools are currently gaining much attention. Advances in material science have resulted in unique nanoscale-based theranostic agents, which provide renewed hope for patients suffering from lung cancer. Nanotechnology has vastly modified and upgraded the existing techniques, focusing primarily on increasing bioavailability and stability of anti-cancer drugs. Nanocarrier-based imaging systems as theranostic tools in the treatment of lung carcinoma have proven to possess considerable benefits, such as early detection and targeted therapeutic delivery for effectively treating lung cancer. Several variants of nano-drug delivery agents have been successfully studied for therapeutic applications, such as liposomes, dendrimers, polymeric nanoparticles, nanoemulsions, carbon nanotubes, gold nanoparticles, magnetic nanoparticles, solid lipid nanoparticles, hydrogels, and micelles. In this Review, we present a comprehensive outline on the various types of overexpressed receptors in lung cancer, as well as the various targeting approaches of nanoparticles. American Chemical Society 2022-12-29 /pmc/articles/PMC9835549/ /pubmed/36643475 http://dx.doi.org/10.1021/acsomega.2c04078 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Sharma, Akshansh Shambhwani, Devanshi Pandey, Sadanand Singh, Jay Lalhlenmawia, Hauzel Kumarasamy, Murali Singh, Sachin Kumar Chellappan, Dinesh Kumar Gupta, Gaurav Prasher, Parteek Dua, Kamal Kumar, Deepak Advances in Lung Cancer Treatment Using Nanomedicines |
title | Advances in Lung
Cancer Treatment Using Nanomedicines |
title_full | Advances in Lung
Cancer Treatment Using Nanomedicines |
title_fullStr | Advances in Lung
Cancer Treatment Using Nanomedicines |
title_full_unstemmed | Advances in Lung
Cancer Treatment Using Nanomedicines |
title_short | Advances in Lung
Cancer Treatment Using Nanomedicines |
title_sort | advances in lung
cancer treatment using nanomedicines |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835549/ https://www.ncbi.nlm.nih.gov/pubmed/36643475 http://dx.doi.org/10.1021/acsomega.2c04078 |
work_keys_str_mv | AT sharmaakshansh advancesinlungcancertreatmentusingnanomedicines AT shambhwanidevanshi advancesinlungcancertreatmentusingnanomedicines AT pandeysadanand advancesinlungcancertreatmentusingnanomedicines AT singhjay advancesinlungcancertreatmentusingnanomedicines AT lalhlenmawiahauzel advancesinlungcancertreatmentusingnanomedicines AT kumarasamymurali advancesinlungcancertreatmentusingnanomedicines AT singhsachinkumar advancesinlungcancertreatmentusingnanomedicines AT chellappandineshkumar advancesinlungcancertreatmentusingnanomedicines AT guptagaurav advancesinlungcancertreatmentusingnanomedicines AT prasherparteek advancesinlungcancertreatmentusingnanomedicines AT duakamal advancesinlungcancertreatmentusingnanomedicines AT kumardeepak advancesinlungcancertreatmentusingnanomedicines |